Home › NDC Lookup › RxCUI directory › RxCUI 2714922

{24 (avutometinib 0.8 MG Oral Capsule [Avmapki]) / 42 (defactinib 200 MG Oral Tablet [Fakz... — RxCUI 2714922

RxNorm drug concept · Brand name pack
RxCUI 2714922 Brand name pack · BPCK ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2714922
Official name{24 (avutometinib 0.8 MG Oral Capsule [Avmapki]) / 42 (defactinib 200 MG Oral Tablet [Fakzynja]) } Pack [Avmapki Fakzynja Co-Pack]
Concept typeBrand name pack (BPCK)
RxNorm statusCurrent RxNorm concept
Also known asAvmapki Fakzynja Co-Pack
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How {24 (avutometinib 0.8 MG Oral Capsule [Avmapki])... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept {24 (avutometinib 0.8 MG Oral Capsule [Avmapki]) / 42 (defactinib 200 MG Oral Tablet [Fakzynja]) } Pack [Avmapki Fakzynja Co-Pack] RxCUI 2714922

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Avutometinib 2714515
    • Defactinib 2714502
  2. Brand names 2

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Avmapki 2714521
    • Fakzynja 2714508
  3. Dose forms 15

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Avutometinib Oral Capsule 2714519
    • Defactinib Oral Tablet 2714506
    • Avutometinib Oral Product 2714517
    • Avutometinib Pill 2714518
    • Defactinib Oral Product 2714504
    • Defactinib Pill 2714505
    • Avutometinib Oral Capsule [Avmapki] 2714525
    • Defactinib Oral Tablet [Fakzynja] 2714512
    • +7 more in this family
  4. Clinical & branded drugs 8

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

  5. Packs 1

    Fixed collections of drugs packaged and sold together, like dose packs.

Showing up to 8 concepts per family — 21 of 28 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

  • Avutometinib 0.8 MG Oral Capsule [Avmapki] SBD · 2714526
  • Defactinib 200 MG Oral Tablet [Fakzynja] SBD · 2714513
  • Avutometinib 0.8 MG [Avmapki] SBDC · 2714522
  • Defactinib 200 MG [Fakzynja] SBDC · 2714509
  • Avutometinib Oral Capsule [Avmapki] SBDF · 2714525
  • Defactinib Oral Tablet [Fakzynja] SBDF · 2714512
  • Avmapki Oral Product SBDG · 2714523
  • Avmapki Pill SBDG · 2714524
  • Fakzynja Oral Product SBDG · 2714510
  • Fakzynja Pill SBDG · 2714511

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2714922 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
71779-0623-01 1 KIT in 1 CARTON (71779-623-01) * 24 CAPSULE in 1 BOTTLE... AVMAPKI FAKZYNJA CO-PACK Verastem Inc. 2025-05-08
Observed labelers: Verastem Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.